Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Association of Cytokeratin 5 and Claudin 3 expression with BRCA1 and BRCA2 germline mutations in women with early breast cancer

Fig. 1

Claudin (CLDN) 3. Positive expression in BRCA1 breast cancer (BC) (a) and negative control (isotypic antibody) (b). Positive CLDN4 expression in BRCA1-mutated BC (c), negative control of CLDN4 (isotypic antibody) (d). Positive CLDN7 in BRCA2 BC (e), negative CLDN7 in BRCA1-related tumor (f), and negative control of CLDN7 (isotypic antibody) (g). Positive CK5 staining in BRCA1 BC (h)

Back to article page